AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$ATAI

Short Glenn Frank sold (to issuer) 42,333 shares of ATAI

Short Glenn Frank (Chief Scientific Officer) sold (to issuer) 42,333 shares of AtaiBeckley Inc. (ATAI) on 2026-09-11.

Original reporting
SEC EDGAR · Short Glenn Frank
Published Sep 11, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ATAI
Neutral
high confidence
Mentioned
$ATAI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATAINeutralLow
01

Why it matters

The sale is routine and unlikely to move the stock, but it adds to the cumulative insider activity record.

02

Market read

Minor insider sell with limited trading relevance.

03

What to watch

Absence of price information prevents assessment of whether the sale was at a discount to market.

Relevance 4/10Novelty 3/10Timing: filed 2026-09-11

Background

Form 4 filings disclose insider transactions; traders monitor them for potential signals.

Company-level read

Ticker impact

$ATAINeutralHigh confidence
Context

Chief Scientific Officer sold 42,333 shares to the issuer via a Form 4 filing on 2026-09-11.

Expected impact

No material move expected; price may dip slightly on perception of insider selling.

Evidence & confidence

The transaction size is modest for a mid‑cap biotech and the CSO held zero shares after the sale, indicating a routine liquidity event rather than a loss of confidence.

Market effects

Sector

No broader sector impact; insider sales are common in biotech.

Regional

Limited to US investors tracking ATAI.

Global

None

Counterpoint

What could challenge this read

If the CSO is cashing out ahead of upcoming trial data, the sell could signal hidden concerns.

Key entities

  • Officer
    Short Glenn Frank

    Chief Scientific Officer of AtaiBeckley Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ATAI insider trading history →

Related articles

SEP 11
$LLYMedAI 8/10

$35 Billion Frog Drug Deal Explained: The Psychedelic Treatment That Could Change Depression Therapy

Eli Lilly is reportedly investing $35 billion in ATAI Life Sciences' psychedelic drug BPL-003, derived from a compound found in the Sonoran Desert toad, for treating depression. Clinical trials showed improvements in treatment-resistant depression patients, but long-term effects are still under study. The drug aims to promote neuroplasticity, potentially helping patients break negative thought patterns. Researchers caution that results do not prove a permanent cure.

vocal.media3 min
SEP 11
$LLYHighAI 9/10

Eli Lilly (LLY) Finalizes $2.8B AtaiBeckley Acquisition for Depression Treatment Pipeline

Eli Lilly (LLY) completed its $2.8B acquisition of AtaiBeckley (ATAI) on September 11, 2026. AtaiBeckley shareholders received $6.75 per share plus contingent value rights (CVRs) worth up to $2.50 per share. AtaiBeckley shares rose 80% in the six months before the deal, closing at $7.35. The company will delist from Nasdaq. LLY shares closed at $1,119.26, down 0.33%.

blockonomi.com2 min
SEP 11
$LLYMedAI 9/10

Lilly Completes AtaiBeckley Acquisition to Expand Mental Health Pipeline

Eli Lilly (LLY) completed its acquisition of AtaiBeckley, adding a clinical-stage portfolio of rapid-acting neuroplastogens to its neuroscience pipeline. The deal expands Lilly's focus on treatment-resistant depression and other mental health conditions, with BPL-003 as the lead program. Financial terms were not disclosed.

citybiz.co2 min
SEP 11
$LLYMedAI 8/10

Share AtaiBeckley Buyout – Minichart

Eli Lilly completed its $6.75-per-share acquisition of AtaiBeckley Inc., taking the company private. Shareholders received $6.75 in cash plus contingent value rights (CVRs) worth up to $2.50 more if milestones are met. AtaiBeckley's stock will be delisted from Nasdaq.

minichart.com.sg2 min